Regulatory milestones

ALK-Abello A/S (CSE:ALK-B) gained DKK4 to DKK420.50 last week after it and partner Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review a BLA from Merck for grass Allergy Immunotherapy Tablet (AIT). Merck said it expects a decision in 1Q14; the specific PDUFA date is not disclosed.